BioSpace News Archive

Ureteroscopy is a procedure in which a telescope-like device is inserted into the bladder and ureter of a person to diagnose and treat problems related to the urinary tract.

Interleukin are group of cytokines that are synthesized by lymphocytes, monocytes, macrophages, and other cells. They regulate cell growth, cell differentiation, and cell motility.

The advent of intraoral imaging technological products into the dental sector is projected to add a boost to the overall growth of the global buccal cavity devices market.

Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19.

Immuneering Corporation announced that several key preclinical datasets highlighting the potential of its lead product candidate, IMM-1-104, will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place virtually from October 7-10, 2021.

ADMA Biologics, Inc. today announced an exclusive educational event at IDWeek 2021 on respiratory viral infections, presented by nationally recognized clinical experts Dr. Michael Ison from Northwestern University and Dr. Jolan Walter from the University of South Florida and Johns Hopkins All Children’s Hospital.

Enanta Pharmaceuticals, Inc. today announced that the company will have two poster presentations showcasing clinical data for EDP-514, a novel pangenotypic class II hepatitis B virus (HBV) core inhibitor, at The Liver Meeting® 2021

Minovia Therapeutics announced today the publication of preclinical data demonstrating that mitochondrial augmentation of CD34+ cells confers functional benefit and that mitochondrial transfer occurs between hematopoietic cells in vivo.

The Phase 2/3 RELATIVITY-047 trial served as the basis for this application, in which a statistically significant and clinically meaningful benefit was observed with relatlimab and nivolumab over Opdivo monotherapy

G1 Therapeutics, Inc., a commercial-stage oncology company, announced that the permanent J-code for COSELA™ that was issued in July 2021 by the Centers for Medicare & Medicaid Services is now effective for provider billing for all sites of care.